Biosensors Perked Up By Japan, China News, Profitability Successes
Executive Summary
CV and critical care company Biosensors is on the brink of a global top 100 medtech company sales ranking: in the first nine months of FY15, it made total sales of US$232.5 million, which would make a year-end total of over $300 million a prospect. Its longer-term strategy is to strengthen its position in the cardiovascular market, expand its geographical reach and add new product lines and investment opportunities to grow into a multi-platformed international player.
You may also be interested in...
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.
An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024
Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.